Sep 18, 2018
Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City
Sep 05, 2018
Trovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to Respond to Onvansertib
Aug 29, 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Aug 16, 2018
Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
Aug 15, 2018
Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
Aug 01, 2018
Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug
Jul 09, 2018
Trovagene Presents Outlook for Second Half of 2018
Jun 27, 2018
Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML
Jun 22, 2018
Trovagene Announces Leadership Change
Jun 15, 2018
Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
May 31, 2018
Trovagene, Inc. Announces Reverse Stock Split
May 17, 2018
Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia
May 08, 2018
Trovagene Announces First Quarter 2018 Highlights and Financial Results
Apr 17, 2018
Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine
Apr 16, 2018
Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
Apr 12, 2018
Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018
Mar 05, 2018
Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
Feb 26, 2018
Trovagene Announces Fourth Quarter and Full-Year 2017 Results
Feb 09, 2018
Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium
Feb 06, 2018
Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)